A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Exclusion Criteria

• •B-ALL participants must have CD20 antigen positive leukaemia
• •Measurable disease at the time of enrolment
• •Participants with Burkitt's lymphoma are eligible for Part B only
• •Central Nervous System (CNS)-only B-cell malignancy, or B-cell malignancy with R/R secondary CNS involvement.
• •Diagnosis or history of chronic lymphocytic leukaemia (CLL) (including large cell \[Richter\] transformation of CLL) or small lymphocytic lymphoma (SLL)
• •Diagnosis or history of cutaneous lymphoma
• •History of another primary malignancy that has not been in remission for at least 3 years before signing informed consent (except for: non-melanoma skin cancer, low grade prostate cancer or carcinoma in situ (e.g., cervix, bladder, breast))
• •Acute or chronic graft-versus-host disease
• •Participant has received donor lymphocyte infusion within 6 weeks prior to INT2104 infusion
• •History of autoimmune disease requiring systemic immunosuppression/ systemic disease modifying agents within 2 years before enrolment
• •History or presence of CNS disorder
• •History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months before signing informed consent
• •Participants has active syphilis, cytomegalovirus (CMV), acute or chronic active hepatitis B, or untreated hepatitis C.
• •Participant is Human immunodeficiency virus (HIV) positive.
• •Any medical condition likely to interfere with assessment of safety or efficacy of the study treatment
• •A vaccine within 4 weeks prior to INT2104 infusion
• •Intolerance or severe hypersensitivity reaction to any excipients of the INT2104 product.
• •An active fungal, bacterial, viral, or other infection that is uncontrolled or requires antimicrobials at the time of INT2104 infusion.
• •Participant is pregnant or nursing.
• •In the investigator's judgment, the participant is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation